Assessment of Subcutaneous vs Intravenous Administration of Anti–PD-1 Antibody PF-06801591 in Patients With Advanced Solid Tumors
- 1 July 2019
- journal article
- research article
- Published by American Medical Association (AMA) in JAMA Oncology
- Vol. 5 (7) , 999-1007
Abstract
Novel antitumor therapies that target the PD-1 (programmed cell death 1) receptor and its ligands (PD-L1 and PD-L2) can reverse cancer-mediated immune evasion.1 The PD-1 receptor is upregulated on activated effector T lymphocytes. Expression of PD-L1 is triggered on tumor cells and other immune cells upon cytokine release by activated T cells, and PD-L2 is mainly expressed on macrophages and dendritic cells.2-4 Binding of the PD-1 receptor to its ligands negatively regulates the antitumor immune response by inhibiting T-cell proliferation, cytokine production, and cytotoxic functions.5,6Keywords
This publication has 40 references indexed in Scilit:
- Subcutaneous versus intravenous bortezomib in two different induction therapies for newly diagnosed multiple myeloma: an interim analysis from the prospective GMMG-MM5 trialHaematologica, 2015
- Preference for subcutaneous or intravenous administration of trastuzumab in patients with HER2-positive early breast cancer (PrefHer): an open-label randomised studyThe Lancet Oncology, 2013
- Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I–III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trialThe Lancet Oncology, 2012
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced CancerNew England Journal of Medicine, 2012
- Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority studyThe Lancet Oncology, 2011
- A modified toxicity probability interval method for dose-finding trialsClinical Trials, 2010
- Tumor antigen–specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impairedBlood, 2009
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009
- PD-1 and Its Ligands in Tolerance and ImmunityAnnual Review of Immunology, 2008
- The B7–CD28 superfamilyNature Reviews Immunology, 2002